Study finds well-known drug may slow muscle loss among the elderly
Humans are living longer than ever. But age-related diseases such as sarcopenia - the loss of muscle mass - are on the rise. Researchers in Basel say a well-known drug might help delay the aging process.
The Swiss generally live long lives. According to the most recent statistics, Swiss men live on average to the age of 81.3, and women to 85.3. But as a natural part of aging, over time people’s muscles lose tone, shrink and strength dwindles.
This condition, known as sarcopenia, affects every second or third person over 80, reducing their mobility, autonomy and quality of life. The causes of sarcopenia are diverse: from altered muscle metabolism to changes in nerves supplying muscles.
A group of scientists at the University of Basel’s BiozentrumExternal link, which has been investigating the question, has identified a key molecular ‘signature’ of sarcopenia. The team, led by Professor Markus Rüegg, have discovered that mTORC1, which acts as a sensor and controls protein synthesis in the body, also contributes to sarcopenia and its suppression with the well-known drug rapamycin slows age-related muscle wasting.
“Contrary to our expectations, the long-term mTORC1 suppression with rapamycin is overwhelmingly beneficial for skeletal muscle aging in mice, preserving muscle size and strength,” declared Daniel Ham, first author of the study.
To encourage other scientists to further investigate how gene expression in skeletal muscle changes during aging or in response to rapamycin treatment, they have created a web application, SarcoAtlasExternal link, which is supported the Centre for Scientific Computing at the University of Basel (sciCORE).
Currently, there is no effective pharmacological therapy to treat sarcopenia. But the scientists say their study gives hope that in the future it may be possible to slow down age-related muscle wasting with treatments that suppress mTORC1 and thereby extend the autonomy and life quality of elderly people.
Popular Stories
More
Foreign affairs
Why Swiss trams have become sought-after vehicles in Ukraine
Switzerland participates in ASEAN foreign ministers’ meeting
This content was published on
This engagement was part of a four-day tour of Southeast Asia, aimed at advancing the Swiss Federal Council's Southeast Asia Strategy.
Majority of shareholders approve sustainability reports of major Swiss companies
This content was published on
Shareholders have approved the sustainability reports of the largest Swiss companies by a large majority at their annual general meetings.
EU releases €1.5B frozen assets to Ukraine: Switzerland opts out
This content was published on
The EU announced the release of €1.5 billion (CHF1.44 billion) in aid to Ukraine. Switzerland will not follow the EU's approach.
Five people charged in connection with deadly Swiss rockslide
This content was published on
Five people have been charged with multiple negligent homicide in connection with the deadly Bondo rockslide that occurred seven years ago.
Mountaineer dies after 100-metre fall from Matterhorn
This content was published on
A women fell down the east face of the iconic mountain on Thursday, from an altitude of some 3,460 meters above sea level.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Heart disease and cancer still biggest causes of death
This content was published on
Cardiovascular disease and cancer were the two most widespread causes of death in Switzerland in 2017, new statistics have shown.
This content was published on
The latest federal health survey of people 55 and older reveals that social factors such as education influence health into old age.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.